Cipla gets USFDA’s final approval for Difluprednate Ophthalmic Emulsion

12 Aug 2021 Evaluate

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (USFDA). Cipla’s Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation’s Durezol.

It is used for the treatment of inflammation and pain associated with ocular surgery and  treatment of endogenous anterior uveitis. According to IQVIA (IMS Health), Durezol had US sales of approximately $106mn for the 12-month period ending June 2021. The product will be available for shipping soon.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1491.40 -3.00 (-0.20%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×